Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–242 of 242
Pigment Epithelium-Derived Factor (PEDF) as a Regulator of Wound Angiogenesis
Michalczyk, E. R., Chen, L., Fine, D., Zhao, Y., Mascariñas, E., Grippo, P. J., & DiPietro, L. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-29465-9 · Cited by 59 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundTaylor, A. P., Rodriguez, M., Adams, K., Goldenberg, D. M., & Blumenthal, R. D. (2003) · International Journal of Cancer · doi:10.1002/ijc.11059 · Cited by 58 · cited 2×
“Despite the existence of other signaling pathways involved in angiogenesis, VEGF/VEGFRs interaction has been considered as a key regulator and constituted an attractive and central target for the development of anti-angiogenic drugs [18–22], the blockade of VEGF signaling pathway by neutralizing antibodies to VEGF or…”
BackgroundPlacental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy
Bagley, R. G., Ren, Y., Weber, W. D., Yao, M., Kurtzberg, L. S., Pinckney, J., Bangari, D. S., Nguyen, C., Brondyk, W. H., Kaplan, J. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2687 · Cited by 58
Al-Wadei, H. A. N., & Schuller, H. M. (2009) · The Journal of Pathology · doi:10.1002/path.2542 · Cited by 52 · cited 1×
“, pancreatic, lung, colon) are able to synthesize and release adrenaline [201,202].”
BackgroundTumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin
Shen, Y., Li, S., Wang, X., Wang, M., Tian, Q., Yang, J., Wang, B., Wang, B., Liu, P., & Yang, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1366-x · Cited by 51
Lopes‐Coelho, F., SILVA, F. A. B. N. D., Gouveia-Fernandes, S., Martins, C., Lopes, N., Domingues, G., Brito, C., Almeida, A. M., Pereira, S. A., & Serpa, J. (2020) · Cells · doi:10.3390/cells9010107 · Cited by 50
Self-citationHaider, K. H., Aziz, S., & Alreshidi, M. A. (2017) · Regenerative Medicine · doi:10.2217/rme-2017-0074 · Cited by 48 · cited 2×
“The limited success of single-targeted monotherapy approaches can be justified by six different mechanisms: (1) The activation of alternative angiogenic signaling pathways; (2) the upregulation of other pro-angiogenic factors [24–28]; (3) the vascular co-option, a process where cancer cells proliferate near the existi…”
BackgroundJin, W., Wu, W., Tang, H. T., Wei, B., Wang, H., Sun, J., Zhang, W., & Zhong, W. (2019) · Marine Drugs · doi:10.3390/md17010052 · Cited by 46
Therapeutic potential of thalidomide and its analogues in the treatment of cancer
Sherbet, G. V. (2015) · PubMed · doi:10.25405/ncl.34305159 · Cited by 43
Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice
de Souza, C. M., de Carvalho, L. F., Vieira, T. D. S., Silva, A. C. A. E., Lopes, M. T. P., Ferreira, M. A. N. D., Andrade, S. P., & Cassali, G. D. (2012) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2012.04.005 · Cited by 42
Mitochondrial damage-induced impairment of angiogenesis in the aging rat kidney
Satoh, M., Fujimoto, S., Horike, H., Ozeki, M., Nagasu, H., Tomita, N., Sasaki, T., & Kashihara, N. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.175 · Cited by 40 · cited 1×
“A study with an aging rat model showed that mitochondrial DNA-deficient kidney cells failed to upregulate VEGF in response to hypoxia due to mitochondrial dysfunction, which contributes to impaired angiogenesis [240].”
BackgroundGarg, J., Feng, Y., Jansen, S. R., Friedrich, J., Lezoualc’h, F., Schmidt, M., & Wieland, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17267 · Cited by 40
Du, W., Hattori, Y., Hashiguchi, A., Kondoh, K., Hozumi, N., Ikeda, Y., Sakamoto, M., Hata, J., & Yamada, T. (2004) · Pathology International · doi:10.1111/j.1440-1827.2004.01622.x · Cited by 37
Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma
Kaicker, S. M., McCrudden, K. W., Beck, L., New, T. N., Huang, J., Frischer, J. S., Serur, A., Kadenhe‐Chiweshe, A. V., Yokoi, A., Kandel, J. J., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.6.1651 · Cited by 36 · cited 1×
“Therefore, the use of thalidomide and analogues as anti-angiogenic drugs has been a focus of cancer research [55,56].”
BackgroundBaicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis
Park, Y.-G., Choi, J., Jung, H.-K., Kim, B., Kim, C., Park, S., & Seol, J.-W. (2017) · Oncology Reports · doi:10.3892/or.2017.6007 · Cited by 35
Li, W., & Zhao, Y. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_32_18 · Cited by 32 · cited 2×
“In prostate cancer xenograft models, β-AR signaling promote tumor angiogenesis [193].”
BackgroundPark, C., Choi, E. O., Kim, G., Hwang, H., Kim, B. W., Yoo, Y. H., Park, H. T., & Choi, Y. H. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.29692 · Cited by 32
Procaccio, L., Damuzzo, V., Sarra, F. D., Russi, A., Todino, F., Dadduzio, V., Bergamo, F., Prete, A. A., Lonardi, S., Prenen, H., et al. (2019) · Drug Safety · doi:10.1007/s40264-018-0776-6 · Cited by 32
Anti-angiogenic Targets: Angiopoietin and Angiopoietin Receptors
Kiss, E. A., & Saharinen, P. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_4 · Cited by 32
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Jones, R. L., Ratain, M. J., O'Dwyer, P. J., Siu, L. L., Jassem, J., Médioni, J., deJonge, M. J. A., Rudin, C. M., Sawyer, M. B., Khayat, D., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.07.024 · Cited by 31
de Souza, C. M., Silva, A. C. A. E., Ferraciolli, C. D. J., Moreira, G. V., Campos, L. C., dos Reis, D. C., Lopes, M. T. P., Ferreira, M. A. N. D., Andrade, S. P., & Cassali, G. D. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.08.004 · Cited by 30
Lee, C., Lee, M. E., Lee, W. S., Kim, J., Park, K.-H., Kim, T. S., Lee, K. Y., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2015) · Europe PMC (PubMed Central) · Cited by 29
Chen, Y., Zhang, S., Peng, G., Yu, J., Liu, T., Meng, R., Li, Z., Zhao, Y., & Wu, G. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1833 · Cited by 29
Semrad, T. J., Kim, E. J.-H., Tanaka, M. S., Sands, J. M., Roberts, C., Burich, R. A., Li, Y., Gandara, D. R., Lara, P. N., & Mack, P. C. (2016) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2016.12.002 · Cited by 29
Maik-Rachline, G., & Seger, R. (2005) · Blood · doi:10.1182/blood-2005-06-2547 · Cited by 28 · cited 1×
“The use of PEGF as a drug has been explored, and different phosphomimetic mutants [106,107] and post-translational modified variants [108,109] with enhanced anti-angiogenic activity were already developed.”
BackgroundNeuropilin 1 guides regulatory T cells into VEGF-producing melanoma
Hansen, W. (2013) · OncoImmunology · doi:10.4161/onci.23039 · Cited by 28
Chen, Y., Bai, N., Bi, J., Liu, X. W., Xu, G., Zhang, L., Li, X., & Huo, R. (2017) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20176138 · Cited by 26
Mirza, M. R., Bergmann, T. K., Mau‐Sørensen, M., Christensen, R. D., Åvall-Lundqvist, E. H., Birrer, M. J., Jørgensen, M. B., Roed, H., Malander, S., Nielsen, F., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03917-z · Cited by 26
Zhao, Y., Liu, F., He, G., Li, K., Zhu, C., Wei, Y., Zhang, C., Xie, M., Lin, J., Zhang, J., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126711 · Cited by 26 · cited 1×
“For instance, in vitro and in vivo results showed that the dual targeting of VEGF and fibroblast growth factor (FGF) pathway inhibited ECs proliferation and migration [37].”
BackgroundHashimoto, H., Sudo, T., Maruta, H., & Nishimura, R. (2010) · PubMed · Cited by 25
Subramanian, P., Deshpande, M. M., Locatelli‐Hoops, S., Moghaddam-Taaheri, S., Gutiérrez, D. A., Fitzgerald, D. P., Guerrier, S., Rapp, M., Notario, V., & Becerra, S. P. (2012) · BioMed Research International · doi:10.1155/2012/425907 · Cited by 25
β-Blockers Promote Angiogenesis in the Mouse Aortic Ring Assay
Stati, T., Musumeci, M., Maccari, S., Massimi, A., Corritore, E., Strimpakos, G., Pelosi, E., Catalano, L., & Marano, G. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000085 · Cited by 25 · cited 1×
“toma, β-blockers (carvedilol, nebivolol, and Propranolol) independently of their selectivity, promoted vincristine-induced tumor regression, in part mediated by the inhibition of tumor angiogenesis [216].”
BackgroundYang, J., Li, G., Bao, K., Liu, W., Zhang, Y., & Ting, W. (2019) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-019-09793-9 · Cited by 23 · cited 1×
“studies suggesting that strategies focused on the generation of ROS and further oxidative stress induce ECs dysfunction, impairing tumor angiogenesis [191,192].”
BackgroundKajiyama, H., Suzuki, S., Yoshihara, M., Nishino, K., Yoshikawa, N., Utsumi, F., Niimi, K., Mizuno, M., Kawai, M., Oguchi, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23921 · Cited by 22
Mechanisms of Action and the Clinical Pharmacology of Beta-Adrenergic Blocking Drugs
Lowenthal, D. T., Saris, S. D., Packer, J., Haratz, A., & Conry, K. (1984) · The American Journal of Medicine · doi:10.1016/s0002-9343(84)80047-9 · Cited by 21
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies
Heil, F., Babitzki, G., Julien-Laferrière, A., Ooi, C.-H., Hidalgo, M. M., Massard, C., Martinez‐García, M., Tourneau, C. L., Kockx, M. M., Gerber, P. A., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100984 · Cited by 21
Argentiero, A., Solimando, A. G., Krebs, M., et al. (2020) · Preprints.org · doi:10.20944/preprints202004.0181.v1 · Cited by 19
Delivery of endostatin in experimental cancer therapy
Sørensen, D. R., & Read, T. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00240.x · Cited by 18
Tumor Angiogenesis: A Key Target for Cancer Therapy
(2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2 · Cited by 15
Prognostic role of the beta-2 adrenergic receptor in clear cell renal cell carcinoma
Ha, M., Kim, D. W., Kim, J., Hong, C. M., Park, S. M., Woo, I. A., Kim, M. Y., Koo, H., Namkoong, J., Kim, J., et al. (2019) · Animal Cells and Systems · doi:10.1080/19768354.2019.1658638 · Cited by 8
Immunotherapy Combinations for the Treatment of Patients with Solid Tumors
Bluthgen, M. V., Basté, N., & Recondo, G. (2020) · Future Oncology · doi:10.2217/fon-2020-0303 · Cited by 8
Jang, H., Kim, B., Kim, D., Kim, J., & Kim, H. (2020) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_797_18 · Cited by 6 · cited 1×
“Unfortunately, the concomitant use of onartuzumab (anti-c-MET) with bevacizumab brought no additional clinical benefits [91,92].”
Background
Research works printed but not linked: 1
- Domingues, G., Fernandes, S.G., and Serpa, J. (2015). Dynamics of VEGF-A and its Receptors in Cancer Vascularization—An Overview. Understand Cancer: Research and Treatment, iConcept Press. Chapter 3.
Cited by
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
VEGF signaling: Role in angiogenesis and beyond
Shaw, P., Dwivedi, S. K. D., Bhattacharya, R., Mukherjee, P., & Rao, G. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189079 · Cited by 215
Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Shang, X., Lu, Y., & Fu, P. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06119-x · Cited by 209
“Most of these agents disrupt the VEGF signaling pathways involved in ECs proliferation and migration, effectively impeding tumor growth [221].”
BackgroundPatil, T. P., Vibhute, A., Patil, S. L., Dongale, T. D., & Pandey-Tiwari, A. (2023) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2023.100372 · Cited by 135
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.